Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2801250 | 0.80 | MMP2 (0.41) | ALDH1A1NAAA | |
| SCHEMBL3593373 | 0.79 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL949382 | 0.75 | NAAA (0.43) | NAAA | |
| SCHEMBL3601324 | 0.74 | CHRNB2 (0.36) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8308785 | 0.69 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30069844 | 0.67 | HTT (0.42) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL3587638 | 0.67 | CNR2 (0.36) | ALDH1A1SMN1; SMN2NAAACHRNB2CHRNA4 | |
| SCHEMBL3590648 | 0.65 | FKBP1A (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL2220133 | 0.61 | KDM4E (0.34) | SMN1; SMN2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL26692202 | 0.61 | DNTT (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728028-B2 | Substituted imidazoline compounds | GRUENENTHAL GMBH (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20090048323-A1 | SUBSTITUTED IMIDAZOLINE COMPOUNDS | GRUENENTHAL GMBH (DE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048323-A1 | SUBSTITUTED IMIDAZOLINE COMPOUNDS | ITCH, OPRK1, ALDH1A1 | ALDH1A1 3/4885SMN1; SMN2 965/4885NAAA 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.